LA
SQZ

Lee Ainslie’s SQZ Biotechnologies Company SQZ Stock Holding History

Lee Ainslie’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,050,286
Closed -$284K – 530
2023
Q2 		$284K Sell
1,050,286
-1,485
-0.1% -$843 0.01% 359
2023
Q1 		$589K Sell
1,051,771
-16,384
-2% -$12.1K 0.01% 213
2022
Q4 		$790K Hold
1,068,155
– – 0.02% 160
2022
Q3 		$2.44M Hold
1,068,155
– – 0.05% 86
2022
Q2 		$3.4M Buy
1,068,155
+11,369
+1% +$40.9K 0.08% 78
2022
Q1 		$5.08M Hold
1,056,786
– – 0.09% 72
2021
Q4 		$9.44M Hold
1,056,786
– – 0.11% 75
2021
Q3 		$15.2M Buy
1,056,786
+73,690
+7% +$999K 0.15% 68
2021
Q2 		$14.2M Buy
983,096
+23,264
+2% +$304K 0.13% 73
2021
Q1 		$13.1M Buy
959,832
+23,861
+3% +$485K 0.12% 65
2020
Q4 		$27.1M Buy
+935,971
New +$23.9M 0.43% 40

Other funds holding SQZ

AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Lee Ainslie's SQZ Position: Q3 2023 in Review

Lee Ainslie sold out of SQZ Biotechnologies Company (SQZ) in Q3 2023, closing a stake of 1,050,286 shares — an estimated $284K sold.

Lee Ainslie first reported a position in SQZ in Q4 2020 and held it in 11 quarters. The position peaked at $27.1M in Q4 2020. 5 funds tracked by Wall St. Rank hold SQZ as of Q3 2023.

  • Lee Ainslie reported no remaining SQZ Biotechnologies Company position as of Q3 2023 after selling out during the quarter.
  • Lee Ainslie sold 1,050,286 SQZ Biotechnologies Company shares in Q3 2023, an estimated $284K.
  • Lee Ainslie first reported a position in SQZ Biotechnologies Company in Q4 2020 and held it in 11 quarters.
  • Lee Ainslie's SQZ Biotechnologies Company position peaked at $27.1M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.